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absTracT In Argentina, the provision of drugs for patients suffering from type 2 dia-
betes mellitus who lack health insurance is carried out through public programs. In the 
Province of Buenos Aires, the national program Remediar and the provincial program 
PRODIABA (from the Spanish Programa de Prevención, Diagnóstico y Tratamiento del 
Paciente Diabético) coexist. This study estimates the percentage of adults in the munici-
pality of Bahia Blanca (Province of Buenos Aires) who suffer from type 2 diabetes melli-
tus and lack health insurance, thus satisfying their need for oral antidiabetic treatments 
within the public sector. It is a quantitative study that assesses the need and demand 
for public provision. The results indicate that: 1) the greatest percentage of demand is 
satisfi ed at the primary health care level; 2) the province of Buenos Aires funds the lar-
gest share of the pills, followed by the municipal and the national levels; 3) the local 
government intervenes to satisfy the demand and 4) the total public provision covers 
approximately 25% of the overall need in relation to the average consumption. This 
shows that despite the presence of these public programs, the provision is insuffi cient 
and thus requires the intervention of the local government even though economic theory 
does not recommend the decentralization of drug purchases.
Key WorDs Diabetes Mellitus; Public Policies; Decentralization; Health Services 
Needs and Demand; Argentina.
resUmen En Argentina, la provisión de fármacos para pacientes con diabetes mellitus tipo 
2 (DM2) sin cobertura de salud se efectúa mediante programas públicos. En la provincia 
de Buenos Aires coexisten el programa Remediar, de nivel nacional, y el Programa de 
Prevención, Diagnóstico y Tratamiento del Paciente Diabético (PRODIABA), de nivel 
provincial. El presente trabajo estima el porcentaje de población adulta con DM2 sin 
cobertura del municipio de Bahía Blanca (provincia de Buenos Aires) con necesidad 
de tratamientos de antidiabéticos orales, que satisface su demanda en el sector público. 
Es un estudio cuantitativo que evalúa la demanda y la necesidad de provisión pública. 
Los resultados indican que: 1) el mayor porcentaje de la demanda se satisface en el 
primer nivel de atención; 2) la provincia de Buenos Aires fi nancia el mayor porcentaje 
de comprimidos, seguida por el nivel municipal y el nacional; 3) el nivel local también 
interviene para satisfacer la demanda y 4) la provisión pública total solo daría cobertura a 
aproximadamente el 25% de las necesidades en el escenario correspondiente al consumo 
medio. Esto muestra que, incluso con diferentes programas públicos, la provisión no es 
sufi ciente y se requiere de la intervención local aun cuando la descentralización en la 
adquisición de fármacos no es recomendada por la teoría económica.
palabras clave Diabetes Mellitus; Políticas Públicas; Descentralización; Necesidades 
y Demanda de Servicios de Salud; Argentina.
36 elorza me, moscoso ns, ripari nv.
SA
LU
D
 C
O
LE
C
TI
V
A
, B
ue
no
s 
A
ire
s,
 8
(1
):3
5-
45
, J
an
ua
ry
 - 
A
pr
il,
 2
01
2
Universidad Nacional de Lanús | Salud Colectiva | English Edition ISSN 2250-5334 | E-ISSN 1851-8265| ISSN-L 1669-2381
inTroDUcTion
The Argentine health care system is organized 
into three sectors: the social security sector, the 
private sector and the public sector. The latter pro-
vides services at the three levels of government (na-
tional, provincial and municipal) through hospitals 
and primary health care centers. The following are 
some of its duties: 1) to ensure medical and health 
coverage to low-income people without health in-
surance and/or with geographical limitations to 
access, and 2) to implement programs to prevent 
and/or control certain pathologies, such as non-com-
municable chronic diseases, which are the leading 
causes of morbidity and mortality worldwide (1). 
Particularly, type 2 diabetes mellitus (T2DM) 
is a common pathology which accounts for 80% 
to 90% of diabetes cases (2). Although genetic 
predisposition is a determining factor (3), type 2 
diabetes is usually triggered by risk factors such as 
obesity, sedentarism and smoking (4,5). It can be 
controlled by changes in lifestyle (6-8) and with 
pharmacological treatments, which frequently in-
volve oral antidiabetic drugs (OAD) (9) such as 
glibenclamide and metformin (10).
The relevance of this disease lies in its high 
and growing prevalence (11,12) as well as to the 
substantial number of premature deaths it causes 
(13). It imposes a considerable socioeconomic 
burden on health systems because, in addition to 
the sizeable direct cost of treatment (14), there are 
high indirect costs due to the loss of work capacity 
(15) as well as intangible costs associated with pain, 
stress and employment discrimination. At the same 
time, the costs of all medical services are greater in 
diabetic patients than in non-diabetic patients (16).
Several research studies have estimated the 
importance of the direct costs of this disease. It was 
noted that in developed countries the expenses in-
curred for insulin and OAD are low in comparison 
with hospitalization expenses (17-20). However, 
according to Oliva et al., if the expenditures for 
insulin and OAD are added to the expenditures for 
other drugs, overall drug expenses exceed hospi-
talization expenses (21). According to Barceló et 
al., in Latin America, pharmacological treatments 
account for 44% of the direct costs of diabetes (22).
Given that in medium and low income coun-
tries between 50% and 90% of the population 
must pay for their medicines (23), free provision 
of pharmacological treatments for this type of dis-
eases represents a key aspect of public policies 
(24). According to a study by the International 
Diabetes Federation, 61% of a wide sample of 
countries including Argentina had implemented 
some type of national diabetes program, usually 
including free provision of drugs (25).
Various authors have identified problems in 
accessing T2DM drugs. According to Mendis et 
al., availability of insulin and some OAD is scarce 
in medium and low-income countries where free 
provision exists (26). Reséndez et al. note that in-
efficiency in drug provision management affects 
OAD availability in some cities in Mexico (27). 
Viera Paniz et al. observe shortages of medica-
tions for diabetics in some cities in Brazil, although 
there are public policies at the different levels of 
government (28).
Although many research studies analyze the 
public policies of drug provision to T2DM pa-
tients, it is important to evaluate these policies 
from a need-demand-supply approach, as the esti-
mated needs of a population do not always match 
the real demand for the drugs under study (29).
In order to estimate the need for health goods 
or services, the epidemiological information on that 
medical condition, the perceptions of individuals, 
or certain objective clinical measurements can be 
used (30). The demand will be strictly related to the 
behavior patterns of the consumption of the goods 
and services under analysis (31). There are several 
factors which make it so that the demand may not 
be equal to the need; for instance, the presence of 
unreported morbidity or of silent disease (32).
From the perspective of economic theory, 
the public provision of drugs should be analyzed 
as a private good distributed publicly, whose ac-
quisition justifies policies with a certain degree of 
centralization due to the presence of economies 
of scale (33). However, preventive policies must 
be regarded as public goods whose provision 
may be analyzed from the perspective of the 
theory of fiscal federalism (34). Within this focus, 
decentralization in the allocation of public goods 
to lower levels of government is justified by the 
gains in welfare obtained through adapting the 
supply to local preferences (35,36).
In Latin America there are numerous local ini-
tiatives in social policy funded, in many cases, by 
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local resources (37). According to Guillen, these 
initiatives involve a special process of decentral-
ization in which local governments decide to 
intervene in certain issues although they are not 
obliged to do so by the institutional framework 
(38). Some research studies indicate that local 
levels are crucial in the provision of a wide range 
of health services (39) because they achieve re-
ductions in the child mortality rate (40). 
However, regardless of the level of gov-
ernment providing the healthcare good or 
service, coordination among all levels is essential 
in order to ensure the impact, efficacy and effi-
ciency of public policies (41). In this respect, 
Peters suggests that coordination problems may 
justify centralized policies, even if this means 
losing the benefits of local policies (42). In the 
case of Latin American drug provision policies, 
although there were huge monetary benefits to 
centralized purchases (43), there were also ex-
tensive losses due to waste, theft and/or expi-
ration when the central level was in charge of the 
distribution (44). In this region evidence suggests 
that there are scarce mechanisms of coordination 
among levels of government (45). This generates 
dispersion in the effects of social public policies 
that pursue the same goals (a) (37).
In Argentina, Act 23753 of 1989 establishes 
that the national level must coordinate the policies 
that ensure drug access, while the provinces must 
ensure free pharmacological treatments to pa-
tients who lack health insurance and economic 
resources (46).
In particular, in the province of Buenos 
Aires, Act 11620 of 1994 seeks to improve the 
quality of life of diabetic patients (47). Based 
on this law, in 1996 the Provincial Program 
for the Prevention, Diagnosis and Treatment of 
Diabetic Patients (PRODIABA, from the Spanish 
Programa Provincial de Prevención, Diagnóstico 
y Tratamiento del Paciente Diabético) was im-
plemented. It includes free provision of drugs to 
patients who lack health insurance and/or eco-
nomic resources.
Additionally, in the context of the 2001 so-
cioeconomic crisis, the National Ministry of 
Health, supported by international credit insti-
tutions, implemented the national public drug 
provision program Remediar, which includes es-
sential drugs such as those used to treat T2DM.
Various authors have assessed the access to 
pharmacological treatments provided by these pro-
grams in the province of Buenos Aires. Marín et al., 
through an epidemiologic research study, estimated 
that the program Remediar in 2004 provided uninter-
rupted annual treatment to only 0.65% of potential 
patients with T2DM (48). However, according to 
Doménech, in the same year PRODIABA provided 
coverage to 43% of the target population (49).
In addition to the programs mentioned above, 
in the municipality of Bahía Blanca (province of 
Buenos Aires) there is another, local initiative, the 
Municipal Program of Drugs for Prevalent Chronic 
Diseases (Programa Municipal de Medicamentos 
para Patologías Crónicas Prevalentes) – hereinafter 
called the Municipal Program – which involves the 
free provision of OAD to patients suffering from 
T2DM who lack health insurance. Therefore, this 
article seeks to analyze in that municipality the 
percentage of the adult population suffering from 
T2DM that lacks health insurance and is in need 
of free OAD treatments that has satisfied their 
demand for medication during the period October 
2008-September 2009.
maTerial anD meTHoDs
Using a quantitative and descriptive study, 
the OAD treatments effectively demanded in the 
public sector were estimated. As the treatments 
demanded are not always equal the treatments 
needed, the percentage of the population needing 
public provision that actually received treatment 
was estimated. This is a retrospective research 
study comprising the period between October 
2008 and September 2009. The treatments con-
sidered in the control of T2DM are metformin 
(500 mg) and glibenclamide (5 mg).
The methodology implemented to estimate 
the adult population suffering from T2DM without 
health insurance in the municipality of Bahía 
Blanca was made up of the following steps:
1. The adult population (between 15 and 65 
years old) in Bahía Blanca in 2008 was ob-
tained via the statistical projection of the 2001 
National Population Census conducted by the 
National Institute of Statistics and Censuses 
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(INDEC, from the Spanish Instituto Nacional 
de Estadísticas y Censos) (50). 
2. The adult population in Bahía Blanca in need 
of drugs for T2DM was estimated using the rate 
of regional diabetes prevalence in the central 
region of Argentina, estimated at 7% (51), and 
the frequency of cases of T2DM within the total 
diabetes cases, estimated at 85% (2).
3. It was calculated that 28% of the population 
estimated above depends on the public pro-
vision of treatments. This estimation comes 
from the percentage of the population without 
health insurance estimated for the Pampean 
Region in 2005 according to the National 
Survey of Risk Factors (52).
In order to estimate the effective demand for 
free treatments of glibenclamide and metformin 
in the municipality the following steps were 
carried out:
1. The free provision of tablets of glibenclamide 
and metformin to the adult population affected 
by T2DM in Bahía Blanca was determined. This 
information was obtained through data pro-
vided by institutions at the different levels of 
government: the Planning Management Office 
of Remediar+Redes (a project of the National 
Ministry of Health in order to promote Primary 
Health Care, at the national level); represen-
tatives of the program PRODIABA in Sanitary 
Region I (at the provincial level); the Diabetes 
Unit of the Endocrinology Department at the 
Dr. José Penna General Interregional Acute 
Care Hospital (Hospital Interzonal General 
de Agudos “Dr. José Penna,” at the provincial 
level); and the Sub-directorate of Management 
and Programs of the Department of Health of 
the Municipality of Bahía Blanca (at the muni-
cipal level).
2. The number of treatments provided by the 
public sector (in monodrug therapy), according 
to the type of drug and prescription dose, was 
estimated. Two dose types were considered, 
which represent minimum and maximum pre-
scription scenarios: 
  Mean daily dose: as proposed for the region 
by the Latin American Association of Diabetes 
(53), this dose is 10 mg for gliberclamide and 
1,700 mg for metformin. In order to convert the 
number of tablets into treatments the following 
formula was applied for each drug: number of 
mean daily doses = available units per year (in 
mg) / mean daily dose (in mg).
  Maximum daily dose: according to the theory 
suggested by Goodman and Gilman (54), this 
is 15 mg for glibenclamide and 2,550 mg for 
metformin. In this case, in order to convert 
tablets into treatments the following formula 
was applied for each drug: number of maximum 
daily doses = available units per year (in mg) / 
maximum daily dose (in mg). 
resUlTs
In accordance with the current regulations, 
patients suffering from T2DM who lack insurance 
and reside in the municipality of Bahía Blanca 
should satisfy their medication needs through 
free provision at the provincial or national level. 
However, even after acknowledging that the 
demand for treatment is usually lower than actual 
need, the local level detected that in the case of 
metformin the treatments available were insuf-
ficient to meet the demand. For that reason, the 
municipality implemented a Municipal Program 
consisting of free provision through the first level 
of health care to patients suffering from chronic 
diseases, including T2DM.
In the Municipality of Bahía Blanca, free distri-
bution of OAD treatments for T2DM is carried out 
by: a) the first level of health care through primary 
health care centers, b) the second level of health 
care through the Dr. José Penna General Interre-
gional Acute Care Hospital and c) the Department 
of Health of the Municipality of Bahía Blanca. 
Table 1 shows public drug distribution by in-
stitution, program and type of drug provided.
The funding of the total public provision of 
each OAD by each level of government shows 
that the provincial level, through PRODIABA, 
funds 87% of glibenclamide tablets and more than 
70% of metformin tablets. At the national level, 
Remediar funds 13% of glibenclamide tablets and 
6% of metformin tablets. As shown in Figure 1, be-
tween them both programs satisfy the local demand 
of glibenclamide, but the municipal level had to 
fund 22% of metformin. 
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At least three significant issues may be noted 
regarding the funding of the tablets provided by 
the public sector: 
1. The low percentage provided by the national 
level through Remediar. However, this can be 
explained by the fact that the program arises in a 
context of health emergency, with the objective 
of improving access to essential drugs through 
the first level of health care, by acting not as the 
only public provider but rather as a complement 
to other funding sources. This panorama stems 
from national legislation which delegates to the 
provincial levels the responsibility for ensuring 
the largest percentage of free coverage of these 
treatments.
2. In aggregate terms, the provincial level funds 
77.2% of the total number of tablets de-
manded, the municipal level 14.3% and, fi-
nally, the national level 8.4%.
Table 1. Public distribution of T2DM medications by program and institution responsible 
for the distribution. Bahía Blanca (Argentina). 2008-2009.
Program Institution responsible for the distribution Drugs
PRODIABA Dr. José Penna General Interregional Acute Care 
Hospital* Insulin, Glibenclamide, Metformin
PRODIABA                Dr. Leónidas Lucero Municipal Acute Care Hospital** Insulin
PRODIABA Department of Health of the Municipality of Bahía 
Blanca**
Glibenclamide, Metformin
Municipal 
Program
Department of Health of the Municipality of Bahía 
Blanca**
Metformin
Remediar Primary health care centers** Glibenclamide, Metformin
Source: Own elaboration using data provided by Health Department officers of the Municipality of Bahía Blanca
PRODIABA= Provincial Program for the Prevention, Diagnosis and Treatment of Diabetic Patients
Municipal Program = Municipal Program of Drugs for Prevalent Chronic Diseases
*Provincial jurisdiction
**Municipal jurisdiction
Figure 1. Funding of public provision of tablets for T2DM treatment by type of drug, 
Bahía Blanca (Argentina). October 2008-September 2009.
PRODIABA Municipal Remediar
n = 552.180
PRODIABA Remediar
n = 294.915
72% 87%
6% 13%
22%
Metformin tablets Glibenclamide tablets
Source: Own elaboration using data from the Planning Management Office of Remediar+Redes, PRODIABA (Provincial Program for the 
Prevention, Diagnosis and Treatment of Diabetic Patients), the Diabetes Unit of the Endocrinology Department of the Dr. José Penna General 
Interregional Acute Care Hospital and the Sub-directorate of Management and Programs of the Department of Health of the Municipality of 
Bahía Blanca.
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3. In terms of the overall cost of the local pro-
vision of metformin, which was $25,000 (USD 
6,313), this intervention does not prove to be 
efficient technically, given that the average 
unit cost paid by the municipality was $0.21 
(USD 0.0530) (c), while the average unit cost 
paid by the national level (through the program 
Remediar) was $0.11 (USD 0.0278) (d).
Finally, to focus on the aim of this work, the 
number of patients who satisfied their annual 
demand of treatments of glibenclamide or met-
formin at no cost was estimated. 
In order to capture the variability of the treat-
ments prescribed to patients, scenarios related to 
the different types of doses were considered. To 
this effect, Table 2 shows the result of converting 
the number of tablets to number of treatments 
by mean daily dose and maximum daily dose, 
using the formulas mentioned in the Material and 
Methods section. 
Considering the different scenarios, it can be 
noted that the annual free treatments provided 
to adult patients suffering from T2DM vary from 
301 to 451 for metformin and from 273 to 410 
for glibenclamide. 
In turn, the pharmacological treatments pro-
vided through the first level of health care account 
for 70% in the case of metformin and 59% in the 
case of glibenclamide. These results underscore 
the importance that primary health care should 
have in the policies of prevention, treatment and 
control of this disease (55).
After estimating the number of patients who 
demanded treatments in the public sector, the adult 
population suffering from T2DM who may need this 
provision was then estimated. The importance of this 
analysis lies in the fact that the need for treatment 
is not always translated into effective demand. In 
our calculation, the population needing public drug 
provision would amount to 3,274 inhabitants. This 
number was arrived at by considering that in the 
Municipality of Bahía Blanca in 2008 there were 
approximately 196,505 adult inhabitants, 13,755 
of whom, approximately, could have been suffering 
from diabetes, according to the 7% rate of preva-
lence estimated for the region. Specifically, 11,691 
could have had T2DM. Within this population, 
3,274 inhabitants suffering from T2DM would not 
have had health insurance, according to the data 
provided for the region in 2005.
However, as with any “silent” disease, a 
high rate of underdiagnosis (that is, people with 
the disease who have not yet been detected) is 
common in diabetes (56). Gagliardino et al. have 
estimated this rate as close to 50% in a population 
in the city of La Plata (Buenos Aires, Argentina) (57).
If this rate of underdiagnosis calculated by 
Gagliardino et al. is assumed for the municipality 
of Bahía Blanca, the population under treatment 
Table 2. Annual treatments estimated for each drug and dose, by program and health 
care level. Bahía Blanca (Argentina). October 2008 - September 2009.
Program Level of 
health care
Annual treatments
Metformin Glibenclamide
Mean daily 
dose
Maximum 
daily dose Mean daily dose Maximum daily dose
PRODIABA First level 188 125 190 127
Municipal First level 97 65 0 0
Remediar First level 29 19 53 35
PRODIABA Second level 137 92 167 111
Subtotals First level 314 209 243 162
Second level 137 92 167 111
Totals 451 301 410 273
Source: Own elaboration using data from the Planning Management Office of Remediar+Redes, PRODIABA, the Diabetes Unit of the 
Endocrinology Department of the Dr. José Penna General Interregional Acute Care Hospital and the Sub-directorate of Management and 
Programs of the Department of Health of the Municipality of Bahía Blanca.
PRODIABA = Provincial Program for the Prevention, Diagnosis and Treatment of Diabetic Patients
Municipal Program  = Municipal Program of Drugs for Prevalent Chronic Diseases
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demanding OAD from the public sector would be 
approximately half of the population diagnosed. 
However, the results of the research study 
suggest that public coverage would account only 
for 26.3% of the treatments needed, considering 
a mean daily dose intake (861 treatments, 451 
of which were of metformin and 410 of gliben-
clamide) and 17.53% of the treatments needed 
considering a maximum daily dose intake (574 
treatments, 301 of metformin and 273 of gliben-
clamide). These results arise from the estimation 
that “the population needing public provision of 
drugs” is approximately 3,274 inhabitants.
It is important to clarify certain limitations of 
this study which could distort the results obtained. 
First, the doses used do not consider those who 
take both drugs, or who treat their disease only 
with diet or insulin (58).
Another weakness lies in the lack of data re-
garding two key aspects: 1) the percentage of the 
population without health insurance who get their 
treatments by buying them out-of-pocket, and 2) 
the percentage of treatments obtained in the mu-
nicipality of Bahía Blanca by patients living else-
where in the region (this could happen primarily 
at the provincial hospital).
 The limitations mentioned above are factors 
that could determine that the population effec-
tively covered by the public policies is smaller or 
larger than the population estimated. Analyzing 
the impact and size of these factors will be the 
focus of our future research.
DiscUssion
The results observed in the municipality of Bahía 
Blanca suggest that the policies of free distribution of 
drugs to patients affected by T2DM in the province 
of Buenos Aires have strengths and weaknesses.
One of the strengths is related to the mech-
anism of distribution used, as the main part of 
the oral anti-diabetic tablets demanded from the 
public system were delivered through the first level 
of health care which, according to the evidence, is 
the appropriate level for managing the detection, 
treatment and prevention of this disease.
The main weakness is the fact that the treat-
ments provided publicly by the national and pro-
vincial level in the municipality under study are 
not sufficient to satisfy the need for metformin. This 
fact motivated the intervention of the local gov-
ernment, thereby demonstrating that the access of 
many diabetic patients was ensured by a voluntary 
decision at the lowest level of government and not 
by the highest levels that are legally responsible 
for the provision of drugs and the coordination of 
policies regarding this disease. 
These results show that, in a key aspect of the 
health sector as is the acquisition of drugs, the lowest 
levels of government intervene even when the 
theory of decentralization, based on the argument 
of economies of scale, does not recommend local 
involvement in this allocation function.
The economic consequences of the national 
and provincial levels not satisfying the demand and 
the need for treatments are: 1) in the short term, 
and in relation to the demand, the technical inef-
ficiency of the public subsector, because the prices 
paid by the local level are higher than the prices 
obtained by programs at the national level (via in-
ternational public bids) or the provincial level (via 
production in provincial laboratories), and 2) in the 
medium term, the results suggest that even with 
public policies implemented in the three levels of 
government, only a small percentage of the patients 
needing pharmacological treatment was covered by 
the public sector. This will result in direct, indirect 
and intangible costs associated with future health 
complications of the patients who are not currently 
receiving uninterrupted treatment of the disease.
final noTes
a. The risk of dispersing efforts within public poli-
cies is assessed within scenarios making up four 
models: the hierarchical coordination model, the 
dispersion model, the donor-recipient model and 
the multilevel government model. In the case of 
Latin America, it is recognized that there is a latent 
risk of dispersion.
b. This percentage equates to 119,140 tablets and 
represents more than half of the tablets delivered 
by PRODIABA in the first level of health care 
(230,000).
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